The looming prospect of American tariffs on pharmaceuticals would likely hit generic drugmakers the hardest, Johnson & ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Indian pharmaceutical companies are ramping up efforts to expand their footprint in the lucrative US oncology generics market, which is currently valued at $145 billion and growing at a robust pace of ...

US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here's what pharma leaders ...

Indian pharmaceutical companies are ramping up efforts to expand their footprint in the lucrative US oncology generics mar ...

Proposed tariffs on pharmaceutical imports could destabilize U.S. generic drug supply, warns Dr. Scott Gottlieb.

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures ...

The global super generics market is on a remarkable growth trajectory, projected to reach USD 413 billion by 2033, up from USD 205 billion in 2023. This impressive rise is fueled by a robust compound ...

The US has raised specific tariff and non-tariff issues related to exports of its pharmaceutical products and medical devices ...

Proposed tariffs in America on imported medications are cause for worry in Bermuda, the head of the Bermuda Health Council has said. BHC chief executive Ricky Brathwaite told The Royal Gazette: ...

Drugmaker Wockhardt has decided to exit its remaining generics business in the US, for commercial reasons.